US FDA News 2/3

top of page

Imfinzi approved for mismatch repair deficient endometrial cancer, fifth indication for AZ's blockbuster | iPharmaCenter

ipharmaservices

Jun 20, 2024

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

ipharmaservices

Jun 19, 2024

FDA Approved Merck’s Keytruda Plus Chemotherapy for Advanced or Recurrent Endometrial Carcinoma

ipharmaservices

Jun 18, 2024

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

ipharmaservices

May 31, 2024

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

ipharmaservices

May 16, 2024

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

ipharmaservices

Apr 30, 2024

FDA Drug Approvals | 2024 | iPharmaCenter

FDA Drug Approvals | 2024 | iPharmaCenter

FDA Drug Approvals | 2024 | iPharmaCenter

ipharmaservices

Apr 20, 2024

FDA approved Orchard Therapeutics' Lenmeldy for juvenile metachromatic leukodystrophy | FDA Approvals | News | iPharmaCenter

FDA approved Orchard Therapeutics' Lenmeldy for juvenile metachromatic leukodystrophy | FDA Approvals | News | iPharmaCenter

FDA approved Orchard Therapeutics' Lenmeldy for juvenile metachromatic leukodystrophy | FDA Approvals | News | iPharmaCenter

ipharmaservices

Mar 20, 2024

FDA Gives Green Light to First Medication for Individuals with Liver Scarring Stemming from Fatty Liver Condition | iPharmaCenter

ipharmaservices

Mar 16, 2024

2023 | FDA Drug Approvals | US Pharma News | iPharmaCenter

2023 | FDA Drug Approvals | US Pharma News | iPharmaCenter

2023 | FDA Drug Approvals | US Pharma News | iPharmaCenter

ipharmaservices

Dec 21, 2023

FDA Greenlights First Treatment for Uncommon Non-Cancerous Growth | FDA Approvals | iPharmaCenter

FDA Greenlights First Treatment for Uncommon Non-Cancerous Growth | FDA Approvals | iPharmaCenter

FDA Greenlights First Treatment for Uncommon Non-Cancerous Growth | FDA Approvals | iPharmaCenter

ipharmaservices

Nov 30, 2023

Chikungunya | Drugs | Vaccines | News | Updates | iPharmaCenter

Chikungunya | Drugs | Vaccines | News | Updates | iPharmaCenter

Chikungunya | Drugs | Vaccines | News | Updates | iPharmaCenter

ipharmaservices

Nov 18, 2023

Project Orbis News | Updates | Truqap approved in the US

ipharmaservices

Nov 18, 2023

FDA-Approved Chronic Weight Management Drug Zepbound, rival to Wegovy

FDA-Approved Chronic Weight Management Drug Zepbound, rival to Wegovy

FDA-Approved Chronic Weight Management Drug Zepbound, rival to Wegovy

ipharmaservices

Nov 12, 2023

UCB potential multi-billion blockbuster Bimzelx approved for plaque psoriasis | FDA | iPharmaCenter

UCB potential multi-billion blockbuster Bimzelx approved for plaque psoriasis | FDA | iPharmaCenter

UCB potential multi-billion blockbuster Bimzelx approved for plaque psoriasis | FDA | iPharmaCenter

ipharmaservices

Oct 18, 2023

Pfizer's Abrysvo approved in US to prevent RSV infection in infants |iPharmaCenter

Pfizer's Abrysvo approved in US to prevent RSV infection in infants |iPharmaCenter

Pfizer's Abrysvo approved in US to prevent RSV infection in infants |iPharmaCenter

ipharmaservices

Aug 22, 2023

Pfizer's Elrexfio approved for heavily pretreated multiple myeloma patients | iPharmaCenter

Pfizer's Elrexfio approved for heavily pretreated multiple myeloma patients | iPharmaCenter

Pfizer's Elrexfio approved for heavily pretreated multiple myeloma patients | iPharmaCenter

ipharmaservices

Aug 14, 2023

FDA gave nod for Zurzuvae to treat postpartum depression but NO to major depressive disorder

FDA gave nod for Zurzuvae to treat postpartum depression but NO to major depressive disorder

FDA gave nod for Zurzuvae to treat postpartum depression but NO to major depressive disorder

ipharmaservices

Aug 5, 2023

FDA Approved RSV treatments | iPharmaCneter

FDA Approved RSV treatments | iPharmaCneter

FDA Approved RSV treatments | iPharmaCneter

ipharmaservices

Jul 17, 2023

BioMarin Pharmaceutical's $2.9 million gene therapy Roctavian was approved for haemophilia A

BioMarin Pharmaceutical's $2.9 million gene therapy Roctavian was approved for haemophilia A

BioMarin Pharmaceutical's $2.9 million gene therapy Roctavian was approved for haemophilia A

ipharmaservices

Jun 29, 2023

bottom of page